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FIVpco is a member of the feline immunodeficiency virus family that is endemic in wild cougar populations. Virus replication is robust in
FIVpco-infected cougars but there are no consequences of infection to cougar survival, fecundity or susceptibility to other infections. Unlike
pathogenic lentiviruses, there is no evidence for positive selection on FIVpco gag or env. To better understand how lentivirus genomes evolve in
natural infections, we evaluated the regulatory region and accessory genes from fourteen full-length FIVpco genomes, which represent the FIVpco
diversity in the Northern Rockies Ecosystem. Our data demonstrate that the two sister groups of FIVpco have each acquired binding sites for
different interferon response factors (IRF). The most variable gene in the FIVpco genome encodes OrfA, although there is no indication that it, or
any other accessory gene, is under positive selection. There is a single-splice acceptor site for vif expression, which is conserved among all
FIVpco genomes. However, there are several putative means to express rev and orfA, which differ between the phylogenetic groups of FIVpco.
Our comparative study on divergent FIVpco genomes indicates that variation in potential gene regulation mechanisms, not changes in structural
proteins, characterize the evolution of FIVpco in natural infections.
© 2007 Elsevier Inc. All rights reserved.Keywords: Evolution; FIVpco; LTR; Accessory genes; Gene regulationIntroduction
The family Retroviridae contains seven groups of viruses,
which share many aspects of viral life history and the function
and genomic organization of structural genes. However, there
are differences among the retroviruses in the number of ac-
cessory genes that are encoded. Accessory genes typically have
regulatory roles in the virus life cycle and may interact with
host proteins. Lentiviruses and spumaviruses have the largest
genomes in the Retrovirus family and encode up to six
accessory genes.
The expression of virus genes is under the control of the
lentivirus long terminal repeat (LTR), which contains binding
sites for both viral and host transcription factors. There is sub-
stantial variation in the LTR of different lentiviruses (Thompson
et al., 1994; Yamada et al., 1995) and evidence that differences in⁎ Corresponding author. Fax: +1 814 865 9131.
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doi:10.1016/j.virol.2007.08.024regulatory regions can affect phenotype. For example, acquisition
of a transcription regulatory site can change tissue tropism and
affect the level of virus production in a stimulated cell (Carvalho
et al., 1993;Maury, 1998; Tsichlis and Lazo, 1991). Further, there
is subtype-specific variation in the HIV-1 LTR that affects viral
replication in vitro (Jeeninga et al., 2000; Naghavi et al., 1999;
van Opijnen et al., 2004).
There are three accessory proteins that share similar
functions among members of the lentivirus family (Strebel,
2003). The accessory proteins are located between pol and env
or at the 3′ end of the viral genome and are produced on
subgenomic messages. All lentiviruses encode a protein that
enhances transcription of the viral genome. In some lenti-
viruses, this transactivating protein interacts with a specific
stem–loop structure in the LTR but in feline immunodeficiency
virus (FIV) and the two small ruminant lentiviruses (visna virus
and caprine arthritis–encephalitis virus, CAEV) enhancement
of viral transcription by the transactivating protein is mediated
through interaction with host proteins (Miller et al., 2000). A
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infectious anemia virus (EIAV) is the viral infectivity factor, Vif.
Recently, research on HIV-1 has shown that Vif can counter the
DNA editing by host cytidine deaminase APOBEC3G on the
viral genome that occurs during reverse transcription (Harris et
al., 2003; Sheehy et al., 2003; Yu et al., 2004; Zhang et al.,
2003). Editing by this cellular deaminase causes a high
frequency of G to A substitutions and, consequently, defective
proviruses (Bishop et al., 2004; Esnault et al., 2005; Kieffer et
al., 2005; Poss et al., 2006). Vif depletes APOBEC3G by
binding to the N-terminal domain of the deaminase and to
an ubiquitin–ligase complex composed of cullin-5 and elongins
B and C through the conserved SLQ(Y/F)LA motif in the C-
terminal portion of Vif (Mehle et al., 2006; Yu et al., 2003). This
motif is similar to that encoded by suppressors of cytokine
signaling (SOCS) proteins, which recruit a multi-subunit
ubiquitin–ligase complex and target activated cytokine-associ-
ated kinases for degradation (Kile et al., 2002). Although the
role of Vif in countering host innate defenses is critical to viral
infectivity, Vif, like other lentivirus accessory proteins, is
clearly a multifunctional protein and it also contributes to the
normal maturation and stability of the virus particle (Akari et al.,
2004; Dettenhofer et al., 2000; Goncalves et al., 1996; Simon
and Malim, 1996).
The third of the common lentivirus accessory proteins is Rev.
Rev is essential for export of unspliced or partially spliced viral
transcripts to the cytoplasm. The viral Gag proteins and
enzymes are produced from a full-length unspliced transcript
while the envelope proteins and accessory genes are expressed
from subgenomic mRNA. Rev itself is produced from a fully
spliced mRNA in primate lentiviruses. In EIAV, Rev is
produced with the transactivating protein (Tat) from a
bicistronic mRNA, which is comprised of four exons. Exclusion
of the third exon reportedly downregulates Rev activity while
maintaining Tat levels (Belshan et al., 1998). Rev is expressed
as both a bicistronic and a multiply spliced, one- and two-exon
mRNA in FIV (de Parseval and Elder, 1999; Zou et al., 1997).
Thus, there are different mechanisms of expressing some of the
lentiviral accessory genes both within and between species. The
use of alternative splicing increases the number of functionally
distinct proteins that can be encoded in the genome in both
viruses and eukaryotic organisms and provides additional
means to regulate gene expression in different tissues and at
different stages of cell differentiation (Garcia-Blanco et al.,
2004; Stamm et al., 2005).
Although FIV causes an acquired immunodeficiency syn-
drome in domestic cats, feline lentiviruses are endemic in
populations of cougars (Puma concolor) and lions (Panthera
leo) and infection does not result in disease (Biek et al., 2006a,b).
We recently demonstrated that recombination is discernable in
the genomes of FIVpco as this virus evolves in an expanding
cougar population (Bruen and Poss, 2007). The regions involved
in recombination are almost exclusively between the end of pol
and the start of env; the region of the lentiviral genome which
encodes viral accessory genes. Our previous studies indicated
that there was no evidence of positive selection on viral env or
pol fragments either within or between infected cougars (Bieket al., 2003). Further, a detailed analyses of all feline lentiviral
Gag proteins indicated that positive selection is not shaping this
viral protein as the virus evolves in cougars or other feline host
species (Burkala and Poss, 2007). However, there is evidence
that viral lineages circulating in the Northern Rockies Ecosystem
differ in phenotype (Blake et al., 2006). Viruses that are endemic
and minimally pathogenic in their host populations may evolve
under different pressures than pathogenic viruses, which can
elicit a strong immune response that drives virus intrahost
evolution. In this report, we evaluated the complete genomes of
fourteen full-length FIVpco genomes, which represent the viral
diversity throughout the study region, to determine the
consequences of virus evolution on viral regulatory regions




The LTR of the FIVpco genomes varies in length from 333 to
357 bp. The majority of gaps occur in the first 70 bp in the
aligned sequences. We evaluated the LTR for the presence of
binding sites that were less than 1% different from those of
established mammalian transcription factors. We further
restricted our search to those binding sites that would be
expected to occur by chance less than 0.05 times in a
randomized 1 kb sequence. Similar to FIV (Chatterji et al.,
2002; Thompson et al., 1994), all FIVpco have a conserved AP1
site located in the first 65 bp of the LTR (Fig. 1). However, the
two sister groups of FIVpco have recognition sites for different
interferon response factors (IRF). IRF-1 enhances transcription
of genes regulated by interferon alpha and gamma. There is a
site for this transcription factor at position 16–24 in the LTR of
sequences that group in the lineage containing JM01, JF6,
YM137 and SR631 (Fig. 1). We previously demonstrated that
these sequences are recombinant and are derived from parental
sequences ancestral to YF125 and YM29 (Bruen and Poss, in
press). However, neither of these parental viruses contains the
IRF-1 site, suggesting that it arose by spontaneous mutation
after the recombination event occurred. The recognition
sequence for IRF-1 in the FIVpco LTR is 99.3% similar to
the site identified in humans and it is expected to occur by
chance 1.9 times in 105 bases. In contrast, all members of group
1 except CoLV contain a binding site for IRF-3. IRF-3 is
induced by virus infection and regulated by phosphorylation.
The binding site reported for IRF-3 is an exact match to that in
the LTR in this FIVpco group with the exception of Mc100, to
which it is 99.3% identical. This site could be expected to occur
once in a 10-kb genome by chance alone, although it is unlikely
that it would arise by chance in each of the phylogenetically
related genomes. Thus, IRF sites, which may enhance virus
replication consequent to an innate interferon response, evolved
independently in the two main FIVpco groups. Neither IRF-1
nor IRF-3 binding sites have been reported to occur in FIV. The
absence of the IRF-3 site in CoLV may be because this isolate
has been maintained in tissue culture for over 15 years. Under
Fig. 1. Phylogenetic relationship of IRF binding sites in FIVpco LTR. A maximum likelihood tree was generated based on the full-length pol of FIVpco using the
appropriate model of evolution determined in ModelTest (Posada and Crandall, 1998). A distantly related FIVpco, PLV-14 (UO3982) (derived from a Florida panther),
is used as an outgroup. The tree is depicted to emphasize the two sister groups (shown as 1 and 2 in the figure). The schematic diagram of the LTR shows the position of
the IRF-1 site (black and white dots) and IRF-3 site (black and white checkerboard) in the two sister groups. ‘X’ indicates that a sequence within the clade does not
contain the IRF site. In the upper group, CoLV is a tissue culture adapted isolate. In the lower group, PLV is the most distantly related sequence, derived from a cougar
on Vancouver Island. The sequences in the lower group that contain the IRF-1 site are all recombinant sequences derived from sequences ancestral to YF125 and
YM29/YF16, neither of which contains the site for IRF-1. The cylinder represents the AP1 site, which is conserved among the FIVpco sequences.
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transcription regulatory site could occur by drift.
Vif
The viral infectivity factor (Vif) is produced from a
subgenomic message. The potential splice acceptor (SA) for
expression of Vif is conserved in the FIVpco alignment. ElevenFig. 2. Coding regions and predicted splice sites of FIVpco genomes. The two arran
reading frame separated by a stop codon and (B) Vif and OrfA in different, partia
acceptors (SA) is displayed under each figure. The strength of predictions for each
SA=N90, Sa=80–89, sa=70–79, no label=b70).base pairs on the 3′ side of the SA recognition motif is a splice
donor (SD) site, which is also conserved among FIVpco se-
quences (Fig. 2). The AUG for Vif is at the end of this SD
recognition sequence. The conservation of the SD suggests that
FIVpco may express downstream accessory genes on multiply
spliced mRNA. Indeed, transcripts utilizing a SD that occurs
within the Vif exon in FIV have been documented (de Parseval
and Elder, 1999).gements of open reading frames are shown with (A) Vif and OrfA in the same
lly overlapping reading frames. The position of splice donors (SD) and splice
site is indicated by capital and small letters (SD=N97, Sd=91–96, sd=87–90,
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basic protein (pI range 9.1–9.6). The N-terminus of the protein
is predicted to be composed of three α-helices; the first of these
carries a net negative charge (Fig. 3). The core of the protein is
dominated by coils and β-sheet structures and is positively
charged. There is no evidence of positive selection on Vif. The
best supported model of codon evolution for Vif is one with two
site classes (ω=0 and ωb1). In fact, over 80% of codons are
under purifying selection. There are strong constraints against
change in the region spanning amino acid 128–141; this entire
region is under purifying selection. The highly conserved
TLQRLA motif thought to be important in APOBEC binding
sits in a helix near the C-terminus. The overall predicted
secondary structures of Vif in FIVpco and FIV are similar with
the exception that the entire N-terminal region of FIV Vif is
predicted to assume an α-helix.
There are two conserved sites for PKC phosphorylation in
FIVpco Vif. The first, a SSK motif at position 8–10, is under
purifying selection. There is a second PKC phosphorylation site
either at position 120–122 or 124–126. Of note, the PKC site at
120–122 occurs in sequences JM01, YM137, and SR631, which
were previously identified to be recombinant in the accessory
gene region, and YM29/YF16, which are related to the parental
sequences that gave rise to these recombinants. All other
FIVpco, including the other recombinant parent strain YF125,
have a conserved PKC site at position 124–126. A potential
casein kinase II (CKII) phosphorylation site occurs at 209–211
in all Vif sequences, including the divergent PLV-14 from a
Florida panther, and is under purifying selection. This site also
occurs in FIV sequences and despite differences in length
between FIVand FIVpco Vif in the C-terminal region, the CKII
phosphorylation site is located 30 amino acids from the
TLQRLA site in all sequences (Fig. 3). This degree of
conservation across highly divergent feline lentiviruses suggests
that phosphorylation of this site may be important in Vif
interaction with the complex of proteins that leads to
ubiquitination and destruction of host cytidine deaminases
such as APOBEC, which can edit viral genomes and render them
defective. It is noteworthy that HIV-1 Vif also has multiple
serine/threonine phosphorylation sites and may be regulated by
phosphorylation (Yang and Gabuzda, 1998; Yang et al., 1996).
OrfA
OrfA is a putative transactivating protein in the FIVpco
genome. In ten of the fourteen genomes, the OrfA coding regionFig. 3. Schematic of predicted secondary structure and motifs for Vif. The amino acid
and β-sheet are indicated by cylinders and arrows, respectively. Intervening regions
containing the motif TLQRLA, which is implicated in HIV-1 Vif for APOBEC associa
white and black diamonds, respectively. All FIVpco sequences have a single PKC s
terminus in recombinant viruses (see text). The larger black diamond signifies a casis in frame with that of Vif (Fig. 2). In these genomes, there is an
intervening sequence of 21 to 31 nucleotides between the stop
codon of Vif and the putative AUG of OrfA. In these sequences,
it is possible that OrfA is produced from a bicistronic mRNA
with Vif. In sequences PLV, SR631, SR631B, and Mc100, the
coding region for OrfA is in a different reading frame than Vif. In
these four genomes, the stop codon terminating Vif is shifted
downstream, which could lengthen Vif from PLV, SR631,
SR631B, and Mc100 by 6, 8, 8, and 13 amino acids, res-
pectively. As mentioned above, there is a conserved SD site
preceding the start of vif. All FIVpco sequences contain a
putative splice acceptor site approximately 100 bp before the end
of Vif that could be used to express OrfA independent of Vif
(Fig. 2). However, substitutions in this region, particularly in the
YM29 lineage and recombinant progeny JM01, YM137, and
SR631 decrease the predicted value of this site to be a SA. In
other feline lentiviruses where transcripts have been identified,
OrfA appears to be expressed from a spliced transcript that
utilizes this SA (de Parseval and Elder, 1999; Zou et al., 1997).
The intervening region from the end of Vif to OrfA is predicted
to have extensive secondary structure. The predicted structures
in this region are varied among the fourteen genomes, but all
have extensive hairpins and all have the OrfA AUG presented in
an open, single stranded configuration (Fig. 4B). Thus, it is
possible that OrfA can be expressed either from a multiply
spliced mRNA or from a bicistronic message with Vif using an
internal ribosome entry site (IRES).
The predicted length of OrfA varies from 105 to 110 amino
acids among the FIVpco sequences. The N-terminal region of
the predicted protein is variable in sequence and length. PLV
has a 6-amino acid insert relative to the other FIVpco genomes.
A poly-glutamate stretch, which varies from 4 to 6 residues, also
contributes to length variation in the N-terminus. PLV has both
Glu and Gln residues in this region. The variation in the N-
terminal region among the sequences is in part responsible for
variation in the predicted isoelectric point of the proteins, which
ranges from 5.2 to 8.7. The N-terminal half of the protein carries
a net negative charge while the C-terminus is positive in all
sequences. All sequences except PLVare predicted to have three
α-helices separated by coil regions with a β-sheet at the C-
terminus (Fig. 4A). This arrangement contrasts with that seen in
FIV OrfA, which is characterized by an α-helix that is predicted
with high confidence and that spans the first 48 amino acids of
the protein. The region that interrupts the N-terminal α-helix is
predicted to be a coil (amino acids 25–33 in Fig. 4) in FIVpco
OrfA and is under purifying selection. This suggests that thereposition is displayed above the figure. Secondary structural elements for α-helix
are predicted to assume a coiled structure. The grey cylinder represents the helix
tion. Protein kinase C and casein kinase II phosphorylation sites are displayed by
ite in the region between amino acid 120–125; this site is shifted toward the N-
ein kinase II phosphorylation site that is conserved in all feline lentiviruses.
Fig. 5. Schematic of Rev predicted secondary structure and motifs. The
depiction of secondary structural elements is as described in Fig. 3.
Fig. 4. Schematic of OrfA protein and RNA predicted secondary structure and motifs. (A) The depiction of protein secondary structural elements and phosphorylation
sites for OrfA is as described in Fig. 3. The hatched area in the first α-helix indicates that the support for a complete helical structure throughout this region is low in
some FIVpco sequences. The longer N-terminal region of PLV is predicted to be a β-sheet but the remainder of the region is an α-helix. (B) A representative RNA
structure predicted for Gc34 for the region between the stop codon terminating vif and the putative start of orfA. The structures from different FIVpco genomes differ
but all have elaborate secondary structures and project the AUG initiating the orfA gene in a single-stranded loop.
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the OrfA proteins from FIVpco and FIV. There are two
predicted protein kinase C phosphorylation sites in OrfA and
both are under purifying selection (Fig. 4A). In contrast to the
variation in the C-terminal portion of FIVpco Vif, the 14 amino
acids at the end of OrfA are under purifying selection and the
stop codon that terminates the protein is conserved among all
sequences. This region includes a cluster of three Cys residues,
CRCLNC, that is conserved among FIVpco OrfA (de Parseval
and Elder, 1999). Like Vif, a two-site class model of codon
evolution is best supported; there is no evidence for positive
selection on OrfA from FIVpco.
Rev
Rev is encoded by two exons. The first is at the 5′ end of the
env open reading frame. The rev/env open reading frame overlaps
that of orfA and the AUG of FIVpco Rev is 24 bp upstream of the
end of the OrfA gene. In contrast, the first exon for FIV Rev does
not overlap that of OrfA; the Rev AUG is 17 nucleotides 3′ of the
end of OrfA. The 5′ portion of the FIV first Rev exon is predicted
to form a stem loop structure in most isolates, which could allow
expression of Rev from a bicistronic message (Chatterji et al.,2002). Empirical studies on FIVpco Rev expression have not
been conducted but there are no potential splice acceptors
predicted near the start of Rev (Fig. 2). Thus expression of FIVpco
Rev may occur by leaky scanning or from an IRES.
There are two conserved potential splice donors at the end of
the first Rev exon in all FIVpco sequences. Differential use of
these sites would result in proteins of 69 or 77 amino acids. There
is a third splice donor in group 1 sequencesCoLV,Mc100,Mc121,
and Gc34 (Fig. 2) that would yield a 145-amino acid protein. The
potential SD site is conserved among all FIVpco genomes but a T
to A substitution in some genomes could render this splice donor
site non-functional. Thus themid-portion of Rev could vary due to
differential use of splice donor sites. Alternatively, the first exon of
Rev could be expressed as a unique mRNA encoding a protein
with a novel function, as has been proposed for FIV (de Parseval
and Elder, 1999) and CAEV (Gazit et al., 1996).
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The open reading frame for this exon is 54 amino acids in length
but the splice acceptor site is within the orf and would result in a
product that is 47 amino acids. The spliced Rev protein is
predicted to consist of three α-helices, a turn, and a C-terminal
α-helix (Fig. 5). The C-terminal exon contains the stretch of
12–15 basic amino acids that in HIV-1 is responsible for both
nuclear localization and binding to the Rev response element
(RRE). FIV Rev does not contain the leucine rich nuclear export
region found in HIV-1 Rev (Pollard and Malim, 1998).
However, all FIVpco Rev, including the highly divergent
PLV-14 from a Florida panther, contain a conserved
LLDXXVLXXL motif in the first exon. All Leu residues in
this motif are under purifying selection.
In conclusion, our analysis of FIVpco genomes indicates that
a principal difference among virus lineages is in the potential for
regulation of gene expression. Specifically, there are unique
transcription factor binding sites in the viral LTR that show
phylogenetic affiliation with the main viral groups. The most
variable gene is OrfA, which is an important transcriptional
activator of the FIV genome and can determine cell tropism in
vitro (Waters et al., 1996). Although there is conservation of
protein sequence and predicted structure of a fully spliced Rev,
there are different splice sites in the first exon, which could lead
to different patterns of expression of the Rev domains. Single
domain Rev may have unique functions at different times of the
viral life cycle in FIVpco as has been described for other
lentiviruses (de Parseval and Elder, 1999; Gazit et al., 1996).
Positive selection is a hallmark of the evolutionary genetics
of the pathogenic lentiviruses, HIV-1 and FIV, but is not evident
as a force shaping FIVpco genes. In fact, the only consistent
molecular genetics feature that distinguishes FIVpco from FIV
is the lack of positive selection on the FIVpco genome (Biek et
al., 2003). Differential expression of genes can provide a fitness
advantage and hence be under selection (King and Wilson,
1975) in populations experiencing different environmental
conditions (Averof and Patel, 1997; Whitehead and Crawford,
2006). Regulation of gene expression may provide differential
fitness in an adapted virus, where any changes in protein




The derivation of the fourteen full-length FIVpco genomes
(EF455603–EF455615, DQ192583) evaluated in this study was
previously described (Bruen and Poss, in press; Poss et al.,
2006). To determine the selection pressure on viral genes, a
maximum likelihood tree was generated in PAUP⁎ (Swofford,
1999) using the optimal model of evolution (Posada, 2002).
Each gene alignment was analyzed using the codon-based
substitution models available in PAML that allow different
values for the parameter ω (Yang, 2004; Yang and Nielsen,
2002). The alignment and tree for each gene was also submitted
to the Hyphy package available from Data Monkey (http://www.datamonkey.org) and selection was assessed using the
fixed effects likelihood method (Pond and Frost, 2005).
Analysis of splice sites and transcription factor binding sites
Splice donor and acceptor sites were determined using pre-
diction methods available at the Berkley Drosophila genome
Project site (http://www.fruitfly.org/seq_tools/splice.html)
(Reese et al., 1997). Splice donor and acceptor sites with
predictive values of 0.87–1.00 and 0.70–100, respectively, are
displayed in Fig. 2.
Putative binding sites for known transmission factors were
determined using TFsearch version 1.3 (http://www.cbrc.jp/
research/db/TFSEARCH.html), which matches sequence frag-
ments in the query with the transcription factor binding site date
base TFMATRIX (Heinemeyer et al., 1998). The score returned
from this search does not reflect the probability of binding.
Therefore, we evaluated sites with a score of 90 or greater using
PROMO version 3.02 (http://alggen.lsi.upc.es) (Farre et al.,
2003; Messeguer et al., 2002), which returns the probability of
finding the matched sequence in 1000 bp of a randomized
sequence of the same nucleotide composition as the query.
Promo uses version 8.3 of TRANSFAC.
Analysis of protein and RNA secondary structure and protein
motifs
Secondary structural elements were determined in PsiPRED
(http://bioinf.cs.ucl.ac.uk/psipred/psiform.html) (Jones, 1999;
McGuffin et al., 2000). Predictions of RNA secondary structure
were determined using MFOLD (Lyngso et al., 1999). The
estimated isoelectric point of predicted proteins was evaluated
in both DNASTAR and the pI compute tool in ExPASy (http://
www.expasy.ch/tools/pi_tool.html). Potential phosphorylation
sites were evaluated using Prosite (http://www.expasy.ch/
prosite/) (Sigrist et al., 2002) and NetPhos vs. 2.0 (http://
www.cbs.dtu.dk/services/NetPhos/) (Blom et al., 1999).References
Akari, H., Fujita, M., Kao, S., Khan,M., Shehu-Xhilaga, A., Adachi,M., Strebel,
A., 2004. High level expression of human immunodeficiency virus type-1Vif
inhibits viral infectivity by modulating proteolytic processing of the Gag
precursor at the p2/nucleocapsid processing site. J. Biol. Chem. 279 (13),
12355–12362.
Averof, M., Patel, N.H., 1997. Crustacean appendage evolution associated with
changes in Hox gene expression. Nature 388 (6643), 682–686.
Belshan, M., Harris, M.E., Shoemaker, A.E., Hope, T.J., Carpenter, S., 1998.
Biological characterization of Rev variation in equine infectious anemia
virus. J. Virol. 72 (5), 4421–4426.
Biek, R., Rodrigo, A.G., Holley, D., Drummond, A., Anderson Jr., C.R., Ross,
H.A., Poss, M., 2003. Epidemiology, genetic diversity, and evolution of
endemic feline immunodeficiency virus in a population of wild cougars.
J. Virol. 77 (17), 9578–9589.
Biek, R., Ruth, T.K.,Murphy, K.M., Anderson Jr., C.R., Johnson,M., DeSimone,
R., Gray, R., Hornocker, M.G., Gillin, C.M., Poss, M., 2006a. Factors
associated with microparasite seroprevalence and exposure risk in Rocky
Mountain cougars. J. Wildlife Disease 42, 606–615.
Biek, R., Ruth, T.K., Murphy, K.M., Anderson, C.R., Poss, M., 2006b.
61M. Poss, H. Ross / Virology 370 (2008) 55–62Examining effects of persistent retrovirus infection on fitness and pathogen
susceptibility in a natural feline host. Can. J. Zool. 84, 365–373.
Bishop, K.N., Holmes, R.K., Sheehy, A.M., Davidson, N.O., Cho, S.J., Malim,
M.H., 2004. Cytidine deamination of retroviral DNA by diverse APOBEC
proteins. Curr. Biol. 14 (15), 1392–1396.
Blake, D.J., Graham, J., Poss, M., 2006. Quantification of Feline immunode-
ficiency virus (FIVpco) in peripheral blood mononuclear cells, lymph nodes
and plasma of naturally infected cougars. J. Gen. Virol. 87 (Pt 4), 967–975.
Blom, N., Gammeltoft, S., Brunak, S., 1999. Sequence and structure-based
prediction of eukaryotic protein phosphorylation sites. J. Mol. Biol. 294 (5),
1351–1362.
Bruen, T.C., Poss, M., 2007. Recombination in feline immunodeficiency virus
genomes from naturally infected cougars. Virology 364 (2), 362–370.
Burkala, E., Poss, M., 2007. Evolution of feline immunodeficiency virus Gag
proteins. Virus Genes 35, 251–264.
Carvalho, M., Kirkland, M., Derse, D., 1993. Protein interactions with DNA
elements in variant equine infectious anemia virus enhancers and their
impact on transcriptional activity. J. Virol. 67 (11), 6586–6595.
Chatterji, U., de Parseval,A., Elder, J.H., 2002. Feline immunodeficiency virusOrfA
is distinct from other lentivirus transactivators. J. Virol. 76 (19), 9624–9634.
de Parseval, A., Elder, J.H., 1999. Demonstration that orf2 encodes the feline
immunodeficiency virus transactivating (Tat) protein and characterization of
a unique gene product with partial rev activity. J. Virol. 73 (1), 608–617.
Dettenhofer, M., Cen, S., Carlson, B.A., Kleiman, L., Yu, X.F., 2000.
Association of human immunodeficiency virus type 1 Vif with RNA and
its role in reverse transcription. J. Virol. 74 (19), 8938–8945.
Esnault, C., Heidmann,O.,Delebecque, F., Dewannieux,M., Ribet, D., Hance, A.J.,
Heidmann, T., Schwartz, O., 2005. APOBEC3G cytidine deaminase inhibits
retrotransposition of endogenous retroviruses. Nature 433 (7024), 430–433.
Farre, D., Roset, R., Huerta, M., Adsuara, J.E., Rosello, L., Alba, M.M.,
Messeguer, X., 2003. Identification of patterns in biological sequences at the
ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 31 (13),
3651–3653.
Garcia-Blanco, M.A., Baraniak, A.P., Lasda, E.L., 2004. Alternative splicing in
disease and therapy. Nat. Biotechnol. 22 (5), 535–546.
Gazit, A.,Mashiah, P., Kalinski, H., Gast, A., Rosin-Abersfeld, R., Tronick, S.R.,
Yaniv, A., 1996. Two species of Rev proteins, with distinct N termini, are
expressed by caprine arthritis encephalitis virus. J. Virol. 70 (4), 2674–2677.
Goncalves, J., Korin, Y., Zack, J., Gabuzda, D., 1996. Role of Vif in human
immunodeficiency virus type 1 reverse transcription. J. Virol. 70 (12),
8701–8709.
Harris, R.S., Bishop, K.N., Sheehy, A.M., Craig, H.M., Petersen-Mahrt, S.K.,
Watt, I.N., Neuberger, M.S., Malim, M.H., 2003. DNA deamination
mediates innate immunity to retroviral infection. Cell 113 (6), 803–809.
Heinemeyer, T., Wingender, E., Reuter, I., Hermjakob, H., Kel, A.E., Kel, O.V.,
Ignatieva, E.V., Ananko, E.A., Podkolodnaya, O.A., Kolpakov, F.A.,
Podkolodny, N.L., Kolchanov, N.A., 1998. Databases on transcriptional
regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res. 26 (1),
362–367.
Jeeninga, R.E., Hoogenkamp, M., Armand-Ugon, M., de Baar, M., Verhoef, K.,
Berkhout, B., 2000. Functional differences between the long terminal repeat
transcriptional promoters of human immunodeficiency virus type 1 subtypes
A through G. J. Virol. 74 (8), 3740–3751.
Jones, D.T., 1999. Protein secondary structure prediction based on position-
specific scoring matrices. J. Mol. Biol. 292 (2), 195–202.
Kieffer, T.L., Kwon, P., Nettles, R.E., Han, Y., Ray, S.C., Siliciano, R.F., 2005.
G→A hypermutation in protease and reverse transcriptase regions of human
immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo.
J. Virol. 79 (3), 1975–1980.
Kile, B.T., Schulman, B.A., Alexander, W.S., Nicola, N.A., Martin, H.M.,
Hilton, D.J., 2002. The SOCS box: a tale of destruction and degradation.
Trends Biochem. Sci. 27 (5), 235–241.
King, M.C., Wilson, A.C., 1975. Evolution at two levels in humans and
chimpanzees. Science 188 (4184), 107–116.
Lyngso, R.B., Zuker, M., Pedersen, C.N., 1999. Fast evaluation of internal loops
in RNA secondary structure prediction. Bioinformatics 15 (6), 440–445.
Maury, W., 1998. Regulation of equine infectious anemia virus expression.
J. Biomed. Sci. 5 (1), 11–23.McGuffin, L.J., Bryson, K., Jones, D.T., 2000. The PSIPRED protein structure
prediction server. Bioinformatics 16 (4), 404–405.
Mehle, A., Thomas, E.R., Rajendran, K.S., Gabuzda, D., 2006. A zinc-binding
region inVif bindsCul5 and determines cullin selection. J. Biol. Chem. 281 (25),
17259–17265.
Messeguer, X., Escudero, R., Farre, D., Nunez, O., Martinez, J., Alba, M.M.,
2002. PROMO: detection of known transcription regulatory elements using
species-tailored searches. Bioinformatics 18 (2), 333–334.
Miller, R.J., Cairns, J.S., Bridges, S., Sarver, N., 2000. Human immunodefi-
ciency virus and AIDS: insights from animal lentiviruses. J. Virol. 74 (16),
7187–7195.
Naghavi, M.H., Salminen, M.O., Sonnerborg, A., Vahlne, A., 1999. DNA
sequence of the long terminal repeat of human immunodeficiency virus type
1 subtype A through G. AIDS Res. Hum. Retrovir. 15 (5), 485–488.
Pollard, V.W., Malim,M.H., 1998. The HIV-1 Rev protein. Annu. Rev. Microbiol.
52, 491–532.
Pond, S.L., Frost, S.D., 2005. Datamonkey: rapid detection of selective pressure
on individual sites of codon alignments. Bioinformatics 21 (10), 2531–2533.
Posada, D., 2002. Evaluation of methods for detecting recombination from DNA
sequences: empirical data. Mol. Biol. Evol. 19 (5), 708–717.
Posada, D., Crandall, K.A., 1998. MODELTEST: testing the model of DNA
substitution. Bioinformatics 14 (9), 817–818.
Poss, M., Ross, H.A., Painter, S.L., Holley, D.C., Terwee, J.A., Vandewoude, S.,
Rodrigo, A., 2006. Feline lentivirus evolution in cross-species infection
reveals extensive G-to-A mutation and selection on key residues in the viral
polymerase. J. Virol. 80 (6), 2728–2737.
Reese, M.G., Eeckman, F.H., Kulp, D., Haussler, D., 1997. Improved splice site
detection in Genie. J. Comput. Biol. 4 (3), 311–323.
Sheehy, A.M., Gaddis, N.C., Malim, M.H., 2003. The antiretroviral enzyme
APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat.
Med. 9 (11), 1404–1407.
Sigrist, C.J., Cerutti, L., Hulo, N., Gattiker, A., Falquet, L., Pagni, M., Bairoch,
A., Bucher, P., 2002. PROSITE: a documented database using patterns and
profiles as motif descriptors. Brief Bioinform. 3 (3), 265–274.
Simon, J.H., Malim, M.H., 1996. The human immunodeficiency virus type 1 Vif
protein modulates the postpenetration stability of viral nucleoprotein
complexes. J. Virol. 70 (8), 5297–5305.
Stamm,S., Ben-Ari, S., Rafalska, I., Tang,Y., Zhang, Z., Toiber, D., Thanaraj, T.A.,
Soreq, H., 2005. Function of alternative splicing. Gene 344, 1–20.
Strebel, K. (2003). Virus–host interactions: role of HIV proteins Vif, Tat, and
Rev. Aids 17 Suppl 4, S25–34.
Swofford, D.L., 1999. PAUP*. Phylogenetic Analysis Using Parsimony (*and
Other Methods) 4.3. Sinauer Associates, Sunderland, Massachusetts.
Thompson, F.J., Elder, J., Neil, J.C., 1994. Cis- and trans-regulation of feline
immunodeficiency virus: identification of functional binding sites in the
long terminal repeat. J. Gen. Virol. 75 (Pt 3), 545–554.
Tsichlis, P.N., Lazo, P.A., 1991. Virus–host interactions and the pathogenesis of
murine and human oncogenic retroviruses. Curr. Top. Microbiol. Immunol.
171, 95–171.
van Opijnen, T., Jeeninga, R.E., Boerlijst, M.C., Pollakis, G.P., Zetterberg, V.,
Salminen, M., Berkhout, B., 2004. Human immunodeficiency virus type 1
subtypes have a distinct long terminal repeat that determines the replication
rate in a host-cell-specific manner. J. Virol. 78 (7), 3675–3683.
Waters, A.K., De Parseval, A.P., Lerner, D.L., Neil, J.C., Thompson, F.J., Elder,
J.H., 1996. Influence of ORF2 on host cell tropism of feline immunode-
ficiency virus. Virology 215 (1), 10–16.
Whitehead, A., Crawford, D.L., 2006. Neutral and adaptive variation in gene
expression. Proc. Natl. Acad. Sci. U. S. A. 103 (14), 5425–5430.
Yamada, H., Miyazawa, T., Tomonaga, K., Kawaguchi, Y., Maeda, K.,
Castellano, M.C., Kai, C., Tohya, Y., Mikami, T., 1995. Phylogenetic
analysis of the long terminal repeat of feline immunodeficiency viruses from
Japan, Argentina and Australia. Arch. Virol. 140 (1), 41–52.
Yang, X., Gabuzda, D., 1998. Mitogen-activated protein kinase phosphorylates
and regulates the HIV-1 Vif protein. J. Biol. Chem. 273 (45), 29879–29887.
Yang, Z., Nielsen, R., 2002. Codon-substitution models for detecting molecular
adaptation at individual sites along specific lineages. Mol. Biol. Evol. 19 (6),
908–917.
Yang, X., Goncalves, J., Gabuzda, D., 1996. Phosphorylation of Vif and its role
62 M. Poss, H. Ross / Virology 370 (2008) 55–62in HIV-1 replication. J. Biol. Chem. %R 17, 10121–10129. doi:10.1074/
jbc.271.17.10121. 271.
PAML: Phylogenetic Analysis Using Maximum Likelihood 3.14.
Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., Yu, X.F., 2003. Induction of
APOBEC3G ubiquitination and degradation by an HIV-1 Vif–Cul5–SCF
complex. Science 302 (5647), 1056–1060.
Yu, Q., Konig, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., Richman, D.,
Coffin, J.M., Landau, N.R., 2004. Single-strand specificity of APOBEC3Gaccounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol.
Biol. 11 (5), 435–442.
Zhang, H., Yang, B., Pomerantz, R.J., Zhang, C., Arunachalam, S.C., Gao, L.,
2003. The cytidine deaminase CEM15 induces hypermutation in newly
synthesized HIV-1 DNA. Nature 424 (6944), 94–98.
Zou, L., Barr, M.C., Hoose, W.A., Avery, R.J., 1997. Characterization of the
transcription map and Rev activity of a highly cytopathic feline
immunodeficiency virus. Virology 236 (2), 266–278.
